Siobhan M Hamon1, Tomás P Griffin2,3, Md Nahidul Islam1,3, Deirdre Wall4, Matthew D Griffin3,5, Paula M O'Shea1. 1. Department of Clinical Biochemistry, Saolta University Health Care Group (SUHCG), Galway University Hospitals, Galway, Ireland. 2. Centre for Diabetes, Endocrinology and Metabolism, Saolta University Health Care Group (SUHCG), Galway University Hospitals, Galway, Ireland. 3. Regenerative Medicine Institute at CÚRAM SFI Research Centre, School of Medicine, National University of Ireland Galway (NUIG), Galway, Ireland. 4. School of Mathematics, Statistics and Applied Mathematics, National University of Ireland Galway (NUIG), Galway, Ireland. 5. Department of Nephrology, Saolta University Health Care Group (SUHCG), Galway University Hospitals, Galway, Ireland.
Abstract
BACKGROUND: Growth differentiation factor-15 (GDF-15), a stress responsive cytokine, is a promising biomarker of renal functional decline in diabetic kidney disease (DKD). This study aimed primarily to establish normative data and secondarily to evaluate the potential utility of GDF-15 in DKD using Roche Diagnostics electrochemiluminescence immunoassay (ECLIA) in an Irish Caucasian population. METHODS: Following informed consent, 188 healthy volunteers and 128 participants with diabetes (72 with and 56 without DKD) were recruited to a cross-sectional study. Baseline demographics, anthropometric measurements and laboratory measurements were recorded. Blood for GDF-15 measurement was collected into plain specimen tubes kept at room temperature and processed (centrifugation, separation of serum, freezing at -80 °C) within 1 h of phlebotomy pending batch analyses. Reference intervals were determined using the 2.5th and 97.5th percentiles for serum GDF-15 concentration. RESULTS: Of 188 healthy participants, 63 failed to meet study inclusion criteria. The reference interval for serum GDF-15 was 399 ng/L (90% confidence interval [CI]: 399-399) - 1335 ng/L (90% CI: 1152-1445). Receiver operator characteristics (ROC) curve analysis for DKD determined the area under the ROC curve to be 0.931 (95% CI: 0.893-0.959; p<0.001). The optimum GDF-15 cutoff for predicting DKD was >1136 ng/L providing a diagnostic sensitivity and specificity of 94.4% and 79%, respectively, and positive likelihood ratio of 4.5:1 (95% CI: 3.4-6.0). CONCLUSIONS: The reference interval for serum GDF-15 in a healthy Irish Caucasian population using Roche Diagnostics ECLIA was established and a preliminary determination of the potential of GDF-15 as a screening test for DKD was made. Further prospective validation with a larger DKD cohort will be required before the cutoff presented here is recommended for clinical use.
BACKGROUND:Growth differentiation factor-15 (GDF-15), a stress responsive cytokine, is a promising biomarker of renal functional decline in diabetic kidney disease (DKD). This study aimed primarily to establish normative data and secondarily to evaluate the potential utility of GDF-15 in DKD using Roche Diagnostics electrochemiluminescence immunoassay (ECLIA) in an Irish Caucasian population. METHODS: Following informed consent, 188 healthy volunteers and 128 participants with diabetes (72 with and 56 without DKD) were recruited to a cross-sectional study. Baseline demographics, anthropometric measurements and laboratory measurements were recorded. Blood for GDF-15 measurement was collected into plain specimen tubes kept at room temperature and processed (centrifugation, separation of serum, freezing at -80 °C) within 1 h of phlebotomy pending batch analyses. Reference intervals were determined using the 2.5th and 97.5th percentiles for serum GDF-15 concentration. RESULTS: Of 188 healthy participants, 63 failed to meet study inclusion criteria. The reference interval for serum GDF-15 was 399 ng/L (90% confidence interval [CI]: 399-399) - 1335 ng/L (90% CI: 1152-1445). Receiver operator characteristics (ROC) curve analysis for DKD determined the area under the ROC curve to be 0.931 (95% CI: 0.893-0.959; p<0.001). The optimum GDF-15 cutoff for predicting DKD was >1136 ng/L providing a diagnostic sensitivity and specificity of 94.4% and 79%, respectively, and positive likelihood ratio of 4.5:1 (95% CI: 3.4-6.0). CONCLUSIONS: The reference interval for serum GDF-15 in a healthy Irish Caucasian population using Roche Diagnostics ECLIA was established and a preliminary determination of the potential of GDF-15 as a screening test for DKD was made. Further prospective validation with a larger DKD cohort will be required before the cutoff presented here is recommended for clinical use.
Authors: Sarah M Moran; Jennifer Scott; Michael R Clarkson; Niall Conlon; Jean Dunne; Matthew D Griffin; Tomas P Griffin; Elizabeth Groarke; John Holian; Conor Judge; Jason Wyse; Kirsty McLoughlin; Paul V O'Hara; Mark A Little; Matthias Kretzler Journal: J Am Soc Nephrol Date: 2021-09-13 Impact factor: 10.121
Authors: Paul Welsh; Dorien M Kimenai; Riccardo E Marioni; Caroline Hayward; Archie Campbell; David Porteous; Nicholas L Mills; Stephen O'Rahilly; Naveed Sattar Journal: Clin Chem Lab Med Date: 2022-08-18 Impact factor: 8.490
Authors: Maria Dolores Sanchez-Niño; Alberto Ortiz; Maria Vanessa Perez-Gomez; Soledad Pizarro-Sanchez; Carolina Gracia-Iguacel; Santiago Cano; Pablo Cannata-Ortiz; Jinny Sanchez-Rodriguez; Ana Belen Sanz Journal: J Nephrol Date: 2021-04-13 Impact factor: 3.902
Authors: Axel C Carlsson; Christoph Nowak; Lars Lind; Carl Johan Östgren; Fredrik H Nyström; Johan Sundström; Juan Jesus Carrero; Ulf Riserus; Erik Ingelsson; Tove Fall; Johan Ärnlöv Journal: Ups J Med Sci Date: 2019-12-05 Impact factor: 2.384
Authors: Xiaohui Bian; Tomás P Griffin; Xiangyang Zhu; Md Nahidul Islam; Sabena M Conley; Alfonso Eirin; Hui Tang; Paula M O'Shea; Allyson K Palmer; Rozalina G McCoy; Sandra M Herrmann; Ramila A Mehta; John R Woollard; Andrew D Rule; James L Kirkland; Tamar Tchkonia; Stephen C Textor; Matthew D Griffin; Lilach O Lerman; LaTonya J Hickson Journal: BMJ Open Diabetes Res Care Date: 2019-12-15
Authors: Christoph C Kaufmann; Amro Ahmed; Achim Leo Burger; Marie Muthspiel; Bernhard Jäger; Johann Wojta; Kurt Huber Journal: Cells Date: 2022-03-08 Impact factor: 6.600